"Oxford University's 'vaccine for the world' is effective, announced Oxford University based in England, UK.
Cristian Carlos. Peninsula 360 Press [P360].
La Universidad de Oxford y la farmacéutica AstraZeneca dieron a conocer los resultados de la vacuna en desarrollo ChAdOx1 nCoV-2019 que combate a la COVID-19 con un 70 por ciento de eficacia promedio, frente al 94.5 por ciento y 95 por ciento que muestran los laboratorios Moderna y Pfizer respectivelyHowever, they point out, this may be the candidate vaccine to be distributed more quickly because the requirements for storage, duplication and distribution are simpler.
No effort against COVID-19 should be overlooked, especially when it comes to a vaccine that fights the new SARS-CoV-2 coronavirus, which has so far left 1,386,596 regrettable deaths worldwide, with the United States having the highest number of confirmed cases per day, reporting 171,980 on Sunday alone.
To arrive at the 70.4 percent effectiveness, Oxford University says:
To obtain such efficacy, two different dose regimens were averaged, where the vaccine efficacy was 90 percent in one and 62 percent in the other. The group with the highest efficacy, 90%, used a halved first dose and a regular second dose. Analysis of the results indicated that this vaccine could reduce transmission of the virus from an asymptomatic SARS-CoV-2 patient.
Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the Oxford Vaccine Trial, said
"These findings show that - in Oxford - we have an effective vaccine that will save many lives. With great excitement, we discovered that the vaccine, in one of our administered dose trials, can be as effective as 90%. If this vaccine regimen is carried out, more people could have access to the vaccine through its distribution," said Pollar, adding that "today's announcement is only possible because of the many volunteers in that trial, and the strong and talented team of researchers deployed around the world.
No cases were reported whose side effects required hospitalization. The sampling required 24,000 volunteers who were selected from April in the United Kingdom, Brazil and South Africa.
For the University of Oxford, it is important that "it can be easily administered in existing health systems", so this vaccine can be stored at 2ºC to 8ºC -35.6ºF to 46.4ºF- and distributed in a similar way to some types of insulin.
It is currently under development in 10 countries for large-scale production, Oxford said.
